NDAINJECTIONINJECTABLE
Approved
Jul 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURITAL (thiamylal sodium) is a barbiturate injectable anesthetic approved in 1954 for use as a general anesthetic and sedative agent. It is administered intravenously to induce anesthesia prior to surgery or diagnostic procedures. The drug works by enhancing GABAergic inhibition in the central nervous system, producing rapid sedation and anesthesia.
LOE Approaching
As a legacy injectable anesthetic approaching loss of exclusivity, this product likely has a small, maintenance-focused commercial team focused on retention in hospital formularies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SURITAL offers limited career growth opportunity but provides valuable experience in managing mature, legacy pharmaceutical products within hospital and perioperative settings. Roles focus on maintaining market position, compliance, and operational efficiency rather than innovation or expansion.
Medical Affairs SpecialistHospital Account Manager
Worked on SURITAL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.